Study S001985

A Phase 4 Multicenter, Randomized, Open-Label, Interventional Study With Pragmatic Elements Investigating the Effectiveness of Tirzepatide Once Weekly Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes in a Real-World Setting

ClinicalTrials.gov record

Registration

Registration: NCT07247084
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 3000
Start: 2025-11-24
Primary completion: 2029-07
Lead sponsor: Eli Lilly and Company
Conditions: Obesity
Interventions: DRUG:Tirzepatide; OTHER:Standard of Care
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPJF

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline, 24 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014151	SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. Rutter MK, Obesity (Silver Spring, Md.)	2026	Randomized trial	PMID 42297568 DOI	cites ClinicalTrials.gov:NCT07247084; registry reference DERIVED:42297568